AperTO - Archivio Istituzionale Open Access dell'Università di Torino

A founder MLH1 mutation in Lynch syndrome families from Piedmont, Italy, is associated with an increased risk of pancreatic tumours and diverse immunohistochemical patterns

This is the author's manuscript

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/143995> since 2020-06-17T13:16:18Z

Published version:

DOI:10.1007/s10689-014-9726-3

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

UNIVERSITÀ DEGLI STUDI DI TORINO

The final publication is available at Springer via <http://dx.doi.org/10.1007/s10689-014-9726-3>

A founder *MLH1* mutation in Lynch Syndrome families from Piedmont, Italy, is associated with an increased risk of pancreatic tumours and diverse immunohistochemical patterns

Iolanda Borelli · Guido C. Casalis Cavalchini · Serena Del Peschio · Monica Micheletti · Tiziana Venesio
· Ivana Sarotto · Anna Allavena · Luisa Delsedime · Marco A. Barberis · Giorgia Mandrile · Paola
Berchialla · Paola Ogliara · Cecilia Bracco · Barbara Pasini

I. Borelli and G.C. Casalis Cavalchini contributed equally to this work

I. Borelli · S. Del Peschio · A. Allavena · P. Ogliara · C. Bracco · B. Pasini
Department of Medical Sciences, University of Turin, Turin, Italy;

I. Borelli · G.C. Casalis Cavalchini · M. Micheletti · M.A. Barberis · C. Bracco · B. Pasini
Medical Genetics Unit, AOU Città della Salute e della Scienza di Torino, Turin, Italy

T. Venesio · I. Sarotto
Unit of Pathology, Institute for Cancer Research and Treatment, Candiolo, Turin, Italy

L. Delsedime
Pathology Unit, AOU Città della Salute e della Scienza di Torino, Turin, Italy

G. Mandrile · P. Berchialla
Department of Clinical and Biological Sciences, University of Turin, Turin, Italy

G. Mandrile
Medical Genetics Unit, San Luigi University Hospital, Orbassano, Italy

Correspondence:

I. Borelli
Department of Medical Sciences
University of Turin
Via Santena 19, 10126 Torino, Italy.
e-mail: iolanda.borelli@unito.it tel: +39 0116334481, fax: +39 0116335181

Electronic supplementary material The online version of this article (doi:[10.1007/s10689-014-9726-3](https://doi.org/10.1007/s10689-014-9726-3)) contains supplementary material, which is available to authorized users.

Abstract

The *MLH1* c.2252_2253delAA mutation was found in 11 unrelated families from a restricted area south-west of Turin among 140 families with mutations in the mismatch repair (MMR) genes. The mutation is located in the highly conserved C-terminal region, responsible for dimerization with the PMS2 protein.

Twenty-five tumour tissues from 61 individuals with the c.2252_2253delAA mutation were tested for microsatellite instability (MSI) and protein expression. We compared the clinical features of these families versus the rest of our cohort and screened for a founder effect.

All but one tumours showed the MSI-High mutator phenotype. Normal, focal and lack of MLH1 staining were observed in 16%, 36% and 48% of tumours, respectively. PMS2 expression was always lost. The mutation co-segregated with Lynch syndrome-related cancers in all informative families. All families but one fulfilled Amsterdam criteria (AC), a frequency higher than in other *MLH1* mutants. This was even more evident for AC II (72.7% versus 57.5%). Moreover, all families had at least one colon cancer diagnosed before 50 years and one case with multiple LS-related tumours. Interestingly, a statistically significant ($p=0.0057$) higher frequency of pancreatic tumours was observed compared to families with other *MLH1* mutations: 8.2% of affected individuals vs 1.6%. Haplotype analysis demonstrated a common ancestral origin of the mutation, which originated about 1550 years ago.

The mutation is currently classified as having an uncertain clinical significance. Clinical features, tissue analysis and co-segregation with disease strongly support the hypothesis that the *MLH1* c.2252_2253delAA mutation has a pathogenic effect.

Keywords Lynch syndrome; *MLH1* mutations; MLH1-PMS2 dimerization; focal immunohistochemical expression; founder effect

Introduction

Lynch syndrome (LS) is an inherited autosomal dominant cancer predisposition caused by deleterious germline mutations in any of four mismatch repair (MMR) genes: *MLH1*, *MSH2*, *MSH6* and *PMS2*.

Individuals affected by LS are at high risk of developing colorectal and endometrial cancer: the most common manifestation of this syndrome are tumours in the proximal colon (from the cecum to the splenic flexure), often synchronous and/or metachronous with an early age at onset (frequently younger than 45-50 years of age). LS also confers an increased risk of developing cancer in several other organs, including ovary, stomach, small bowel, urothelium and central nervous system (CNS) [1,2]. As a consequence of loss of MMR function, neoplastic cells from individuals with LS show an absent or altered expression of the protein corresponding to the mutated gene and a generalized genomic instability, which is particularly evident at microsatellite loci. Both features can be demonstrated on tumour specimens by immunohistochemistry and microsatellite analysis.

The MMR proteins work as heterodimers: *MLH1* dimerizes with *PMS2* and *MSH2* with *MSH6*. In the absence of the usual partner, *MLH1* can dimerize with *PMS1* or *MLH3* and *MSH2* with *MSH3* [3,4].

The majority of Lynch families have constitutional mutations in either *MSH2* or *MLH1* while *MSH6* and *PMS2* are less frequently involved. Recently, a 5-tiered classification scheme to constitutional variants in *MLH1*, *MSH2*, *MSH6* and *PMS2*, ranging from non pathogenic / low clinical significance (Class 1) to pathogenic (Class 5), has been proposed by The International Society for Gastrointestinal Hereditary Tumours (InSiGHT) [5].

Germline mutations in *MLH1* have been identified throughout the entire gene, and are frequently located in the ATP binding domain and in the C-terminal region which is responsible for constitutive dimerization with the *PMS2* protein [6-9].

Founder mutations, i.e. inherited by numerous descendants of a common ancestor, have been reported in the MMR genes associated with LS [10-21].

We characterized a cohort of patients belonging to 11 LS families carrying the c.2252_2253delAA terminal mutation in the *MLH1* gene. Aim of this work was to evaluate the clinical effect of this mutation and its possible founder origin given the high frequency in LS patients from Piedmont (Italy), particularly in the Turin area.

Patients and methods

Subjects and samples

The c.2252_2253delAA in *MLH1* exon 19 was found in 11 apparently unrelated families among 140 families harbouring germline MMR mutations (51 in *MLH1*, 74 in *MSH2* and 15 in *MSH6*) identified in index cases undergoing genetic analysis for suspected LS in the Turin Medical Genetics Unit from 2001 to middle 2013. Two hundred and seventy-eight control subjects from Piedmont were tested for the presence of the c.2252_2253delAA mutation.

Signed informed consent was obtained from all subjects included in this study, which fulfilled the policies of the local ethical committee. For each family, geographical origin was collected and pedigrees were reconstructed collecting information about the relatives' surnames going back three to five generations: no evidence that the 11 families are closely related was found.

The families carrying the c.2252_2253delAA mutation are listed in Table 1.

Histological samples from 23 bowel and 2 endometrial tumours (13 from probands and 10 from family members) were retrieved for microsatellite analysis and immunohistochemistry. All tumours were revised for classification according to the WHO recommendations [22,23].

DNA extraction

Constitutional DNA of probands, family members and controls was obtained from peripheral blood using the QIAamp DNA Blood Mini kit (Qiagen GmbH, Hilden, Germany) according to the manufacturer's instructions.

Paraffin embedded tumour sections 7-10 µm thick were manually microdissected to obtain samples with tumour cells purity over 80%. After deparaffinization, DNAs from both tumour and normal mucosa were isolated following an overnight digestion with lysis buffer and proteinase K (Qiagen GmbH).

Immunohistochemistry

Immunohistochemistry (IHC) was performed on formalin-fixed, paraffin-embedded tissues. Slides were incubated with mouse monoclonal antibodies against MLH1 (clone G168-15; BD PharMingen, San Diego, CA, USA), MSH2 (clone G219-1129; BD PharMingen), MSH6 (clone 44; BD Transduction Laboratories, San Jose, CA, USA), and PMS2 (clone A16-4; BD PharMingen) proteins. Visualization

was performed by application of HRP-linked secondary antibody (EnVision DakoCytomation, Glostrup, Denmark) and diaminobenzidine [24-26]. Immunohistochemistry analysis results have been confirmed on a different sample from the same cancer.

Detection of Microsatellite Instability

Microsatellite Instability (MSI) status was tested matching the length of three mononucleotide microsatellite markers (BAT25, BAT26 and BAT40) between tumour and normal DNA from all 25 available cancers. A tumour was considered to have high microsatellite instability (MSI-H) if at least 2/3 of the amplified markers were unstable [24,27].

DHPLC, MLPA and sequencing

Screening for point mutations was performed by DHPLC analysis (Transgenomic, Inc., Omaha, NE, USA). PCR products with heteroduplex profiles were sequenced on an ABI 3100 Avant sequencer (Applied Biosystems, Foster City, CA, USA). Large deletions were screened using SALSA MLPA KIT P003 MLH1/MSH2 [28], according to the manufacturer's instructions (MRC-Holland, Amsterdam, The Netherlands). Genotyping of the 278 controls was performed by DHPLC analysis.

RNA extraction and transcript analysis

The RNA of selected cases (M1/19-4, M1/19-6 and M1/19-7) was extracted from blood collected in PAXGene RNA blood tubes (PreAnalytics GmbH, Hombrechtikon, Switzerland) using the PAXgene Blood RNA kit (Qiagen GmbH). The cDNA was generated with the TranscripT first strand cDNA synthesis kit (Roche Diagnostics GmbH, Mannheim, Germany). Reverse Transcription-PCR amplification was performed using forward (M1-18F: AATTGGGACGAAGAAAAGGAA) and reverse (M1-3'UTR2: AAAGGAATACTATCAGAAGGCAAG) primers for exon 18 and exon 19 (3'UTR), respectively.

Mutation Nomenclature and reference sequence

Mutations were named following HGVS recommendations [29]. The *MLH1* gene and mRNA reference sequences are NG_007109.2 and NM_000249.3, respectively. Markers positions on chromosome 3 are derived from the UCSC Genome Browser, GRCh37/hg19 assembly (<http://genome.ucsc.edu/>)

Haplotype analysis

Data analysis from HapMap (release 24, CEU population) and Haploview v. 4.11 [30] led to the identification of six Tag SNPs (Table 2). The rs193922366 ins/del polymorphism in the 3'UTR region of *MLH1* was also analyzed. Ten additional microsatellites were retrieved from UCSC (GRCh37/hg19) to complete the study. In total, 17 polymorphic markers spanning 7.8 Mb on chromosome 3 were tested. Markers' location on chromosome 3 and physical distance are shown in Fig. 1.

Statistical Analysis

Adjusted chi-squared statistic [31] was used to test homogeneity of proportions between groups from family-clustered data.

The age of the *MLH1* c.2252_2253delAA mutation was estimated using DMLE+2.3, which uses Markov Chain Monte Carlo algorithm for Bayesian estimation [32]. For the population growth a rate of 1.05 fold per generation was considered according to Risch et al [33]. Genotyped markers included 7 SNPs and 10 microsatellites.

Results

Eleven apparently unrelated index cases undergoing genetic analysis for suspected LS were found to carry the same mutation in the last exon of *MLH1*, c.2252_2253delAA (p.Lys751Serfs*3). The mutation leads to a frameshift in the mRNA and a hypothetical shorter protein due to the generation of an early stop codon after the insertion of two novel amino acids at codons 751 and 752. The c.2252_2253delAA mutation was not found in 278 controls from the Piedmont population and is not reported in the Exome Variant Server (NHLBI GO Exome Sequencing Project (ESP), Seattle, WA, <http://evs.gs.washington.edu/EVS/>, accessed March 2014, release ESP6500SI-V2 including 6503 samples).

cDNA analysis, performed on 3 of 11 index cases, showed in all samples the balanced presence of both the wild-type and the r.2252_2253delAA transcript (as shown in Online Resource 1).

We subsequently extended the analysis to 61 relatives: the mutation was present in all the 12 subjects affected by LS related cancers. Among 49 healthy relatives the predictive test led to the identification of 14 additional mutation carriers, all under 50 years of age at the moment of testing (Table 1).

Clinical features of the 11 families are summarized in Table 1 and pedigrees are available as Online Resource 2. Ten of the 11 families fulfilled the Amsterdam criteria (AC) while one family met the Bethesda criteria. Compared to the rest of the cohort (140 mutated families overall), *MLH1* c.2252_2253delAA mutant families fulfilled AC more frequently than other *MLH1* mutants (90.9% versus 80%), and this was more evident for AC II (72.7% versus 57.5%). All *MLH1* c.2252_2253delAA mutant families had at least one colon cancer diagnosed before 50 years of age and at least one case with multiple LS related primary tumours (the latter were present in 70% of other *MLH1*, 77% of *MSH2* and 66.6% of *MSH6* mutant families). It is noteworthy that 7/11 families (63.6%) had more than one case with multiple LS related primary tumours, compared to 35% of other *MLH1*, 33.8% of *MSH2* and 13.3% of *MSH6* mutant families (see Online Resource 3).

Altogether, the median age at onset of the first LS related cancer in *MLH1* c.2252_2253delAA mutant families was 49 years (from 23 to 80 years): at diagnosis 30/56 subjects (53.6%) were younger than 50, fifteen of which were below 40 years of age. Among all LS related tumours, 59/86 (68.6%) were colorectal cancers; 37.7% of affected individuals showed LS related extra-colonic cancers at onset from the endometrium, pancreas, stomach, small bowel, biliary tract and central nervous system (CNS). In particular, pancreatic cancer was more frequent (5 tumours among 61 affected individuals, 8.2%) compared to affected subjects from families with other *MLH1* (1.6%, $p=0.0057$), *MSH2* (2.4%, $p=0.04$) and *MSH6* (3.8%, $p=n.s.$) mutations. Overall, pancreatic cancer was present in 5/11 (45.4%) of *MLH1* c.2252_2253delAA families. No tumours of the upper urinary tract or the ovary nor sebaceous skin neoplasias were observed.

Table 3 describes the histological features of available tumour specimens from carriers of the c.2252_2253delAA germline mutation. Of the 25 reviewed tumours, 23 were adenocarcinomas of the bowel and 2 of the endometrium (endometrioid type). Twelve out of 25 (48%) were moderately differentiated, 8 (32%) poorly differentiated and 5 (20%) well differentiated. Among bowel tumours, 11

out of 23 (47.8%) had a mucinous component (<50%), 6 (26.1%) were mucinous, and the remaining 6 (26.1%) had no mucinous component.

High MSI was found in all but one analyzed tumours (96%), in which low MSI was found, a proportion similar to *MSH2* carriers in our cohort (94.6%) but slightly higher than carriers of other *MLH1* mutations (91.3%) or *MSH6* mutations (82.3%). Immunohistochemistry (Fig. 2) showed complete loss of the MLH1 protein in only 12/25 (48%) cancers; 9/25 cancers (36%) showed a focal staining with or without weakened intensity, whereas in 4/25 specimens (16%) MLH1 was normally expressed. For comparison purpose, analysis of 43 tumour tissues from individuals with other *MLH1* mutations, all located outside exon 19, showed a normal MLH1 expression in 7 (16.2%) and a focal expression in 1 (2.3%) cancers.

Five of the seven cancers with normal MLH1 expression were from carriers of splicing mutations. In particular, 3 cancers were from carriers of the c.545+3A>G mutation, for which cDNA analysis was not performed by us but has been shown to cause aberrant splicing leading to the creation of a premature stop codon [34] and 2 from carriers of the c.589-2A>G mutation, for which cDNA analysis showed the skipping of the first 4 bases of exon 8 leading to a frameshift and the creation of a premature stop codon. The remaining mutations in which a normal MLH1 expression was observed were an *in frame* deletion in exon 16 and a truncating mutation in exon 18. The colon cancer with focal MLH1 expression was from a female carrier of the splicing defect c.589-17T>A in which RNA-cDNA analysis showed the *in frame* retention of the last 15 nucleotides of intron 7.

Normal MLH1 expression was found in normal mucosa adjacent to cancer in all samples. In the 23 tumours from individuals with the c.2252_2253delAA mutation tested for PMS2 expression, the protein was always lost. MSH2 and MSH6 were normally expressed in all tested cancers. A second sample from the same tissue was tested for each of the 25 analysed tumours, with no discordant results.

Haplotypes were reconstructed by genotyping all available informative relatives from 8 families, excluding families M1/19-7, M1/19-8 and M1/19-9 in which only the index case was available. A unique haplotype segregates with the c.2252_2253delAA mutation in all fully informative families spanning 1.7 Mb from marker 16xTG to 18xGA, while markers centromeric and telomeric to this region are not shared by all mutated families (Table 4). This haplotype belongs to a single CEU haplotype as defined by data analysis of 6 SNPs from HapMap and Haploview (marked as haplotype number 2 in Table 2) and includes the CTT deletion polymorphism in the 3'UTR of *MLH1* (c.*35_*37delCTT, rs193922366).

In family M1/19-8, for which only the index case was available, the markers' phase was deduced on the basis of the CEU haplotypes: only two SNPs' phases were possible, one of which coincided with the "mutated" haplotype. This was not possible for the index case of family M1/19-7 in which different phases were possible, while M1/19-9 was homozygote for the SNPs defining CEU "haplotype 2".

It is noteworthy that the genotypes of the 4 families that aren't fully informative are compatible with the same 1.7 Mb haplotype mentioned above (Table 4).

The age of the c.2252_2253delAA mutation predicted by the DMLE+2.3 software is 62 generations (95% CI: 28-96), corresponding to about 1550 years.

The wild-type haplotypes identified in our families are listed in Online Resource 4 and match 6 out of 8 CEU haplotypes as defined by tag SNPs. Taking into consideration microsatellites, 23 different haplotypes were defined. The shared region in wild-type haplotypes spans about 0.1 Mb, compared to 1.7 Mb in the "mutated" haplotype. Only two haplotypes (2.pol), both belonging to CEU "haplotype 2", carry the rs193922366 delCTT polymorphism and overlap with the "mutation-haplotype" for the same 0.1 Mb region mentioned above, but differ for the majority of microsatellites.

Discussion

The *MLH1* c.2252_2253delAA mutation is the most frequently recurring LS mutation found in our laboratory: apart from a *MSH2* exon 8 deletion with founder effect identified in 8 Sardinian families [21], the other recurrent mutations were found in 2 to 4 different families only. Overall, 21.6% of the families with a *MLH1* mutation identified in our laboratory carried the c.2252_2253delAA mutation. The six other recurrent *MLH1* mutations found in our cohort have not been tested for a founder effect.

The c.2252_2253delAA mutation has previously been reported in the InSiGHT LOVD database (<http://www.insight-group.org/variants/database/>) in a Korean family [35-37], a Danish family [38], and in three other occurrences as unpublished data from the UK, Germany and Australia. No details about families nor tumour tissue analysis are available.

Two different mutations involving the same nucleotides are also reported in the LOVD database. The missense variant c.2252A>G (p.Lys751Arg) has been classified as likely not pathogenic (Class 2). The duplication c.2252_2253dupAA, which leads to a frameshift in the mRNA and is predicted to result in a protein longer by 26 amino acids, has been reported in three different families either with MSI-H and lack

of MLH1 expression [39], MSS (no information on MLH1 expression) [40] or in which tumour tissue had not been tested [41] and has been classified as uncertain (Class 3). The finding of both deletions and duplications of the same nucleotides in different cohorts may be explained by presence of three consecutive Adenines in the position c.2251_2253.

Many founder mutations associated with LS have been reported in the *MLH1* gene [10-15]. In Italy, a founder *MLH1* mutation was found in six Lynch families originating from a relatively small geographic area of Northern Italy [42,43] and three other have been described in Southern Italy [44].

Haplotype analysis of the 11 families with the c.2252_2253delAA mutation showed a shared haplotype spanning 1.7 Mb in all 8 fully informative families. It is of note that the heterozygous markers in the three remaining families are compatible with this “mutation-haplotype”. The shared haplotype includes the CTT deletion in the 3’UTR region, which is present in only two wild-type haplotypes (see Online Resource 4). As these matched the “mutation-haplotype” for some 0.1 Mb, we can assume that the c.*35_37delCTT deletion was the first mutational event on the ancestral “CEU 2” haplotype, followed by further recombination or microsatellite mutations, and lastly by the occurrence of the c.2252_2253delAA mutation, about 1550 years ago.

The evidence of a common ancestor obtained by haplotype analysis is coherent with the geographical origin of the 11 families, all from a 45 km-wide area south of Turin, Piedmont.

Clinical data showed a high cancer incidence in families carrying the c.2252_2253delAA mutation. A higher proportion of families fulfilled AC compared to other *MLH1* mutants, and this was more evident for AC II. All families had at least one colon cancer diagnosed before 50 years of age and at least one case with multiple LS related primary tumours; almost two-thirds of the families had more than one case with multiple LS related primary tumours.

A high frequency of extra-colonic cancer was observed in subjects with the c.2252_2253delAA mutation. Interestingly, pancreatic cancer was significantly more frequent compared to carriers of other *MLH1* mutations. Overall, 45.4% of families reported the presence of pancreatic cancer. This is higher than the frequencies reported up to date in other surveys, none of which was over 25% [45-47]. Our data are evocative of an increased pancreatic cancer risk in families with the c.2252_2253delAA mutation. Since haplotype analysis demonstrated a common origin of the 11 families, we cannot rule out that the observed increased frequency of pancreatic cancer is actually due to another shared factor of genetic

predisposition. However, to our knowledge no genes with a demonstrated role in pancreatic cancer are located inside the haplotype shared by the families carrying the mutation.

No tumours of the upper urinary tract and the ovary were observed. This is consistent with published data, as they are more frequently observed in *MSH2* [48] and *MSH6* [49] mutated families, respectively.

Tissue analysis showed high microsatellite instability in all but one tested tumours from subjects with the c.2252_2253delAA mutation.

In contrast, complete loss of MLH1 expression was found in only about half of the analyzed tumours, whereas about one third had focal immunostaining and the remaining had normal expression. Unusual staining patterns have been previously reported and do not seem to depend on the anti-MLH1 antibody used [50]. It has been suggested that different kinds of second hits can result in variable MLH1 immunostaining patterns in tumours of individuals carrying the same germinal mutation [51]. The possible association of the c.2252_2253delAA mutation with different somatic mutations in the wild type allele may lead to different expression patterns, from the complete absence of the MLH1 protein to the complete expression of a non-functional protein product. Immunohistochemistry analysis results support this hypothesis, considering that in all three cases in which distinct tumours from the same patient were analyzed, clearly different immunostaining patterns were observed (Table 3).

A positive IHC staining may be explained by the presence of a mutant MLH1 protein catalytically inactive but antigenically intact. This has been shown for some missense mutations in the N-terminal ATPase pocket or in the C-terminal PMS2 binding region, which show an impaired MMR activity and no decrease in protein expression [52-54]. Normal MLH1 expression, however, has also been described in tumours from subjects with small and large in-frame deletions and truncating mutations [51,55]. As the c.2252_2253delAA mutation is located in the last exon of *MLH1*, it is unlikely that the mutant mRNA is degraded by *nonsense-mediated decay (NMD)* [56]. Accordingly, Sanger sequencing of cDNA by 3 different carriers showed the balanced presence of both the wild-type and mutated transcripts (as shown in Online Resource 1). It is of note that Sanger sequencing is not a quantitative method and may therefore miss small imbalances that might be detected using more sensitive techniques (i.e. primer extension). The

presence of the mutated transcript, however, does not necessarily imply that the mutant MLH1 protein is correctly expressed nor stable.

It has been previously reported that terminal MLH1 defects prevent the formation of a stable complex with PMS2, resulting in an impaired DNA mismatch repair function [6,9]. Although dimerization is not required for nuclear localization, the MLH1-PMS2 heterodimer is imported in the nucleus more efficiently than either MLH1 or PMS2 monomers [57]. While the MLH1 protein is stable when expressed alone, PMS2 is quickly degraded if not bound to MLH1 [9].

The c.2252_2253delAA mutation is predicted to abolish 6 of the last 8 MLH1 amino acids, which are highly conserved in the evolution of eukaryotes (as shown in Online Resource 5) and therefore, even if the mutant MLH1 protein is expressed, it is likely that binding to PMS2 is impaired. Accordingly, PMS2 expression was lost in all analyzed tumour samples from individuals carrying the c.2252_2253delAA mutation.

In our cohort, a normal MLH1 expression was not limited to tumours from individuals with the c.2252_2253delAA mutation as it was observed with the same frequency in tumours from individuals with other *MLH1* mutations, all of which located outside exon 19 and all but one resulting in a stop codon. Unfortunately, data about IHC testing for PMS2 is not available for these cases as it was not routinely performed years ago.

Although the mechanism leading to MLH1 protein focal expression has not been clarified, it is noteworthy that in our experience this abnormal pattern has not been identified in patients with other *MLH1* mutations, with the exception of one tumour from a subject with a different *MLH1* mutation, a splicing defect leading to the *in frame* retention of the last 15 nucleotides of intron 7.

The antigenic epitopes for the four anti-MMR antibodies are particularly sensitive to fixation and therefore immunostaining patterns should only be assessed in well-fixed regions of the tissue section [26]. In our experience of immunohistochemistry analysis, only few tumour tissues have shown weak, focal or weak focal MMR protein staining. These expression patterns, however, were usually seen for more than one protein in the same specimen and were interpreted as inadequacy of the sample. In the present study we did exclude that focal staining was due to tissue poor preservation, since normal MLH1 expression was found in the normal mucosa adjacent to cancer in all samples, or to an erroneous interpretation due to the mucinous component of the tumour; moreover MSH2 and MSH6 proteins were normally

expressed in the nuclei of both cancer and normal mucosa of all samples. The focal MLH1 expression was unrelated to histological features of the analyzed tumours (cancer site, grading, mucinous component). We can speculate that this very terminal frameshift mutation leads to a MLH1 protein not only unable to hetero-dimerize with PMS2 but also less stable and/or with a less efficient nuclear import as a monomer, which would explain its proper expression in only a few nuclei.

The c.2252_2253delAA mutation has been classified as Class 3 (uncertain) by the Variant Interpretation Committee of the InSiGHT, mainly due to insufficient evidence. No familial or clinical data about previously reported cases is available.

Our data strongly support the hypothesis that the *MLH1* c.2252_2253delAA mutation has a pathogenic effect. The mutation is predicted to abolish 6 of the highly conserved last 8 amino acids of MLH1, in the C-terminal region which is responsible for constitutive dimerization with the PMS2 protein. Accordingly, all tested tumours from individual with the mutation lack PMS2 expression and all but one show MSI-H. The mutation co-segregates with disease in all informative families: it is noteworthy that all healthy subjects who were over 50 years of age at the moment of testing, including four aged 61-77, do not carry the mutation. The mutated families showed clinical features typical of LS including tumours at young age and multiple primary tumours in the same subject. Moreover, a high frequency of pancreatic cancer was observed.

The c.2252_2253delAA mutation was absent in control subjects from the same Italian region and has not been reported as a normal polymorphism in the general population.

Since haplotype analysis demonstrated a single origin of the mutated allele, we cannot rule out that the cause of LS in the 11 tested families is actually an unidentified *MLH1* mutation residing on the same haplotype. This however is unlikely considering that the c.2252_2253delAA mutation has been reported in other two families ascertained for LS in different populations.

Conflict of interest

The authors declare no conflict of interest

Acknowledgements

We thank Prof. Nicola Migone, for the precious advice and for providing the MLH1 multiple alignment and evolutionary evaluation, Dr Patrizia Pappi for sequences purification and technical support on microsatellite analysis and Mrs. Katia Pollato for further technical support on IHC and microsatellite analysis.

References

1. Vasen HF, Watson P, Mecklin JP, Lynch HT (1999) New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. *Gastroenterology* 116 (6):1453-1456
2. Umar A, Boland CR, Terdiman JP et al (2004) Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. *J Natl Cancer Inst* 96 (4):261-268
3. Acharya S, Wilson T, Gradia S, et al (1996) hMSH2 forms specific mispair-binding complexes with hMSH3 and hMSH6. *Proc Natl Acad Sci U S A* 93 (24):13629-13634
4. Guerrette S, Acharya S, Fishel R (1999) The interaction of the human MutL homologues in hereditary nonpolyposis colon cancer. *J Biol Chem* 274 (10):6336-6341
5. Thompson BA, Spurdle AB, Plazzer JP et al (2014) Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database. *Nat Genet* 46 (2):107-115
6. Kondo E, Suzuki H, Horii A, Fukushige S (2003) A yeast two-hybrid assay provides a simple way to evaluate the vast majority of hMLH1 germ-line mutations. *Cancer Res* 63 (12):3302-3308
7. Raevaara TE, Korhonen MK, Lohi H et al (2005) Functional significance and clinical phenotype of nontruncating mismatch repair variants of MLH1. *Gastroenterology* 129 (2):537-549
8. Mohd AB, Palama B, Nelson SE, Tomer G, Nguyen M, Huo X, Buermeyer AB (2006) Truncation of the C-terminus of human MLH1 blocks intracellular stabilization of PMS2 and disrupts DNA mismatch repair. *DNA Repair* 5 (3):347-361

9. Kosinski J, Hinrichsen I, Bujnicki JM, Friedhoff P, Plotz G (2010) Identification of Lynch syndrome mutations in the MLH1-PMS2 interface that disturb dimerization and mismatch repair. *Hum Mutat* 31 (8):975-982
10. Moisio AL, Sistonen P, Weissenbach J, de la Chapelle A, Peltomaki P (1996) Age and origin of two common MLH1 mutations predisposing to hereditary colon cancer. *Am J Hum Genet* 59 (6):1243-1251
11. Jager AC, Bisgaard ML, Myrhoj T, Bernstein I, Rehfeld JF, Nielsen FC (1997) Reduced frequency of extracolonic cancers in hereditary nonpolyposis colorectal cancer families with monoallelic hMLH1 expression. *Am J Hum Genet* 61 (1):129-138
12. Borrás E, Pineda M, Blanco I et al (2010) MLH1 founder mutations with moderate penetrance in Spanish Lynch syndrome families. *Cancer Res* 70 (19):7379-7391
13. van Riel E, Ausems MG, Hogervorst FB et al (2010) A novel pathogenic MLH1 missense mutation, c.112A > C, p.Asn38His, in six families with Lynch syndrome. *Hered Cancer Clin Pract* 8 (1):7
14. Therkildsen C, Isinger-Ekstrand A, Ladelund S et al (2012) Cancer risks and immunohistochemical profiles linked to the Danish MLH1 Lynch syndrome founder mutation. *Fam Cancer* 11 (4):579-585.
15. Tomsic J, Liyanarachchi S, Hampel H et al (2012) An American founder mutation in MLH1. *Int J Cancer* 130 (9):2088-2095
16. Foulkes WD, Thiffault I, Gruber SB et al (2002) The founder mutation MSH2*1906G-->C is an important cause of hereditary nonpolyposis colorectal cancer in the Ashkenazi Jewish population. *Am J Hum Genet* 71 (6):1395-1412
17. Chan TL, Chan YW, Ho JW et al (2004) MSH2 c.1452-1455delAATG is a founder mutation and an important cause of hereditary nonpolyposis colorectal cancer in the southern Chinese population. *Am J Hum Genet* 74 (5):1035-1042
18. Lynch HT, Coronel SM, Okimoto R et al (2004) A founder mutation of the MSH2 gene and hereditary nonpolyposis colorectal cancer in the United States. *JAMA* 291 (6):718-724
19. Stella A, Surdo NC, Lastella P et al (2007) Germline novel MSH2 deletions and a founder MSH2 deletion associated with anticipation effects in HNPCC. *Clin Genet* 71 (2):130-139
20. Perez-Cabornero L, Borrás FE, Infante SM et al (2011) Characterization of new founder Alu-mediated rearrangements in MSH2 gene associated with a Lynch syndrome phenotype. *Cancer Prev Res (Phila)* 4 (10):1546-1555

21. Borelli I, Barberis MA, Spina F et al (2013) A unique MSH2 exon 8 deletion accounts for a major portion of all mismatch repair gene mutations in Lynch syndrome families of Sardinian origin. *Eur J Hum Genet* 21 (2):154-161
22. Hamilton SR, Bosman FT, Boffetta P et al (2010) Carcinoma of the colon and rectum. In: Bosman FT, Carneiro F, Hruban RH, Theise ND (eds) *WHO Classification of Tumours of the Digestive System*, 4th edn. IARC Press, Lyon, pp 134-146
23. Silverberg SG, Kurman RJ, Nogales F, Mutter GL, Kubik-Huch RA, Tavassoli FA (2003) Epithelial tumours and related lesions. In: Tavassoli FA, Devilee P (eds) *Pathology and Genetics. Tumours of the breast and female genital organs*, IARC Press, Lyon, pp 221-232
24. Ruzskiewicz A, Bennett G, Moore J, Manavis J, Rudzki B, Shen L, Suthers G (2002) Correlation of mismatch repair genes immunohistochemistry and microsatellite instability status in HNPCC-associated tumours. *Pathology* 34 (6):541-547
25. Hansen TP, Nielsen O, Fenger C (2006) Optimization of antibodies for detection of the mismatch repair proteins MLH1, MSH2, MSH6, and PMS2 using a biotin-free visualization system. *Appl Immunohistochem Mol Morphol* 14 (1):115-121
26. Shia J (2008) Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. *J Mol Diagn* 10 (4):293-300
27. Boland CR, Thibodeau SN, Hamilton SR et al (1998) A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. *Cancer Res* 58 (22):5248-5257
28. Gille JJ, Hogervorst FB, Pals G, Wijnen JT et al (2002) Genomic deletions of MSH2 and MLH1 in colorectal cancer families detected by a novel mutation detection approach. *Br J Cancer* 87 (8):892-897
29. den Dunnen JT, Antonarakis SE (2000) Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. *Hum Mutat* 15 (1):7-12
30. Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. *Bioinformatics* 21 (2):263-265

31. Donner A, Eliasziw M, Klar N (1994) A comparison of methods for testing homogeneity of proportions in teratologic studies. *Stat Med* 13 (12):1253-1264
32. Reeve JP, Rannala B (2002) DMLE+: Bayesian linkage disequilibrium gene mapping. *Bioinformatics* 18 (6):894-895
33. Risch N, de Leon D, Ozelius L et al (1995) Genetic analysis of idiopathic torsion dystonia in Ashkenazi Jews and their recent descent from a small founder population. *Nat Genet* 9 (2):152-159
34. Pensotti V, Radice P, Presciuttini S et al (1997) Mean age of tumour onset in hereditary nonpolyposis colorectal cancer (HNPCC) families correlates with the presence of mutations in DNA mismatch repair genes. *Genes Chromosomes Cancer* 19 (3):135-142
35. Han HJ, Yuan Y, Ku JL et al (1996) Germline mutations of hMLH1 and hMSH2 genes in Korean hereditary nonpolyposis colorectal cancer. *J Natl Cancer Inst* 88 (18):1317-1319
36. Yuan Y, Han HJ, Zheng S, Park JG (1998) Germline mutations of hMLH1 and hMSH2 genes in patients with suspected hereditary nonpolyposis colorectal cancer and sporadic early-onset colorectal cancer. *Dis Colon Rectum* 41 (4):434-440
37. Shin YK, Heo SC, Shin JH, Hong SH, Ku JL, Yoo BC, Kim IJ, Park JG (2004) Germline mutations in MLH1, MSH2 and MSH6 in Korean hereditary non-polyposis colorectal cancer families. *Hum Mutat* 24 (4):351-358
38. Nilbert M, Wikman FP, Hansen TV et al (2009) Major contribution from recurrent alterations and MSH6 mutations in the Danish Lynch syndrome population. *Fam Cancer* 8 (1):75-83
39. Pistorius SR, Kruppa C, Haas S et al (2000) Clinical consequences of molecular diagnosis in families with mismatch repair gene germline mutations. *Int J Colorectal Dis* 15 (5-6):255-263
40. Wolf B, Henglmüller S, Janschek E et al (2005) Spectrum of germ-line MLH1 and MSH2 mutations in Austrian patients with hereditary nonpolyposis colorectal cancer. *Wien Klin Wochenschr* 117 (7-8):269-277
41. Sheng JQ, Fu L, Sun ZQ et al (2008) Mismatch repair gene mutations in Chinese HNPCC patients. *Cytogenet Genome Res* 122 (1):22-27
42. Caluseriu O, Di Gregorio C, Lucci-Cordisco E et al (2004) A founder MLH1 mutation in families from the districts of Modena and Reggio-Emilia in northern Italy with hereditary non-polyposis colorectal cancer associated with protein elongation and instability. *J Med Genet* 41 (3):e34

43. Ponz De Leon MP, Benatti P, Di Gregorio C et al (2007) Genotype-phenotype correlations in individuals with a founder mutation in the MLH1 gene and hereditary non-polyposis colorectal cancer. *Scand J Gastroenterol* 42 (6):746-753
44. Lastella P, Patruno M, Forte G et al (2011) Identification and surveillance of 19 Lynch syndrome families in southern Italy: report of six novel germline mutations and a common founder mutation. *Fam Cancer* 10 (2):285-295
45. Kastrinos F, Mukherjee B, Tayob N et al (2009) Risk of pancreatic cancer in families with Lynch syndrome. *JAMA* 302 (16):1790-1795
46. Geary J, Sasieni P, Houlston R, Izatt L, Eeles R, Payne SJ, Fisher S, Hodgson SV (2008) Gene-related cancer spectrum in families with hereditary non-polyposis colorectal cancer (HNPCC). *Fam Cancer* 7 (2):163-172
47. Barrow E, Robinson L, Alduaij W, Shenton A, Clancy T, Lalloo F, Hill J, Evans DG (2009) Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. *Clin Genet* 75 (2):141-149
48. van der Post RS, Kiemeny LA, Ligtenberg MJ et al (2010) Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers. *J Med Genet* 47 (7):464-470
49. Pal T, Akbari MR, Sun P et al (2012) Frequency of mutations in mismatch repair genes in a population-based study of women with ovarian cancer. *Br J Cancer* 107 (10):1783-1790
50. Hendriks Y, Franken P, Dierssen JW et al (2003) Conventional and tissue microarray immunohistochemical expression analysis of mismatch repair in hereditary colorectal tumors. *Am J Pathol* 162 (2):469-477
51. Mangold E, Pagenstecher C, Friedl W et al (2005) Tumours from MSH2 mutation carriers show loss of MSH2 expression but many tumours from MLH1 mutation carriers exhibit weak positive MLH1 staining. *J Pathol* 207 (4):385-395
52. Borrás E, Pineda M, Brieger A et al (2012) Comprehensive functional assessment of MLH1 variants of unknown significance. *Hum Mutat* 33 (11):1576-1588
53. Takahashi M, Shimodaira H, Andreutti-Zaugg C, Iggo R, Kolodner RD, Ishioka C (2007) Functional analysis of human MLH1 variants using yeast and in vitro mismatch repair assays. *Cancer Res* 67 (10):4595-4604

54. Hinrichsen I, Brieger A, Trojan J, Zeuzem S, Nilbert M, Plotz G (2013) Expression defect size among unclassified MLH1 variants determines pathogenicity in Lynch syndrome diagnosis. *Clin Cancer Res* 19 (9):2432-2441
55. Wahlberg SS, Schmeits J, Thomas G, Loda M, Garber J, Syngal S, Kolodner RD, Fox E (2002) Evaluation of microsatellite instability and immunohistochemistry for the prediction of germ-line MSH2 and MLH1 mutations in hereditary nonpolyposis colon cancer families. *Cancer Res* 62 (12):3485-3492
56. Frischmeyer PA, Dietz HC (1999) Nonsense-mediated mRNA decay in health and disease. *Hum Mol Genet* 8 (10):1893-1900
57. Leong V, Lorenowicz J, Kozij N, Guarne A (2009) Nuclear import of human MLH1, PMS2, and MutLalpha: redundancy is the key. *Mol Carcinog* 48 (8):742-750

Fig. 1 Markers used to define the haplotypes carrying the *MLH1* c.2252_2253delAA mutation

- a) Map of the markers surrounding the *MLH1* gene
- b) Zoom-in of the region in which the tag SNPs are located. The position of rs193922366 (a three-nucleotide ins/del: CTT/-) is also shown. The mutation is shown as a *hollow circle*

Fig. 2 Immunohistochemical staining of mismatch repair proteins

a) absent MLH1 staining in colon cancer cells (left) and positive nuclear staining in normal colon mucosa (right); b1) focal MLH1 nuclear staining in colon cancer cells and b2) positive intense MLH1 staining in adjacent normal mucosa; c) positive nuclear MLH1 staining in colon cancer.
d) absent PMS2 nuclear staining in colon cancer expressing MLH1 (left, same tumour of panel c) and positive staining in normal mucosa (right)
(x 200 magnification)

Table 1 Clinical features of Lynch Syndrome families with the *MLH1* c.2252_2253delAA mutation

Family ID	Clinical criteria ^a	No. individuals affected by LS cancers ^b	Median age at onset of the first LS cancer (min-max age)	No. Individuals with Colorectal cancers	No. Colorectal cancers	No. Endometrial cancers	No. Gastric (Small bowel) cancers	No. Pancreatic (Biliary tract) cancers	CNS cancers ^c	No. individual with synchronous tumours (No. of tumours)	No. individuals with multiple primary tumours	No. individuals affected by non-LS cancers or unknown site	No. positive for the mutation / total affected relatives for confirmatory testing.	No. positive for the mutation / total healthy relatives with predictive testing.
M1/19-1	AC-I	5	68 (46-79)	5	7	0	0 (0)	0 (0)	0	1 (2)	2	0	0	1/4
M1/19-2	AC-II	4	51.5 (38-69)	4	4	1	0 (0)	0 (1)	0	0 (0)	2	4	0	0/3
M1/19-3	AC-II	3	43 (35-44)	1	1	1	1 (1)	1 (0)	0	0 (0)	2	0	1/1	3/4
M1/19-4	AC-II	13	56 (26-80)	6	6	3	2 (1)	1 (0)	2	0 (0)	2	3	5/5	8/24
M1/19-5	AC-II	7	44.5 (30-53)	6	8	2	1 (0)	0 (0)	0	1 (3)	2	0	3/3	1/4
M1/19-6	AC-II	8	46.5 (35-61)	7	12	0	0 (0)	1 (0)	0	2 (3 and 4)	2	0	1/1	0/4
M1/19-7	AC-I	3	66 (23-67)	3	4	0	0 (0)	0 (0)	0	0 (0)	1	1	0	0
M1/19-8	AC-II	5	43 (37-60)	4	4	0	0 (0)	1 (0)	1	0 (0)	1	4	0	0
M1/19-9	AC-II	7	51 (39-76)	4	5	1	1 (0)	0 (0)	1	0 (0)	1	2	0	0
M1/19-10	AC-II	4	40 (36-59)	3	3	1	0 (0)	1 (0)	1	0 (0)	1	3	1/1	1/3
M1/19-11	BR	2	(38-49)	2	5	0	0 (0)	0 (0)	0	0 (0)	2	0	1/1	0/3

^a Clinical criteria: AC-I (Amsterdam criteria type 1), AC-II (Amsterdam criteria type 2), BR (revised Bethesda criteria)

^b Number of individuals affected by Lynch syndrome (LS) tumours: colorectal, endometrial, gastric, small bowel, pancreatic, biliary tract, central nervous system (CNS). No ovarian and upper urinary or sebaceous cancers were present

^c CNS tumours have not been included in the median calculation because medical records were not available for confirmation

Table 2 CEU haplotypes defined by selected tag SNPs

SNPs	Gene	CEU Haplotypes							
		1	2	3	4	5	6	7	8
rs1800743	<i>MLH1</i>	G	G	A	G	G	A	A	G
rs3774341	<i>MLH1</i>	C	A	A	C	A	A	A	C
rs1799977	<i>MLH1</i>	G	A	A	A	A	A	G	A
rs1558528	<i>MLH1</i>	A	C	C	A	C	C	C	C
rs9876116	<i>MLH1</i>	G	A	A	G	A	A	A	G
rs749072	<i>LRRFIP2</i>	T	T	C	T	C	T	C	T
Haplotype frequencies: %		33.3	26.6	17.5	15.0	4.1	1.6	1.6	0.8

Table 3 Histological features of 25 cancers from individuals with the *MLH1* c.2252_2253delAA mutation

Subject ID ^a	Cancer site	WHO Classification of Tumours			MS-status	IHC			
		Histological diagnosis	Differentiation grading	Mucinous component: %		MLH1	MSH2	MSH6	PMS2
M1/19-1	rectum	adenoma with invasive carcinoma	well	5	MSI-H	loss	No loss	No loss	loss
M1/19-1	caecum	adenocarcinoma	moderately	40	MSI-H	No loss	No loss	No loss	loss
M1/19-1.2	caecum	adenocarcinoma	moderately	>50	MSI-H	weak focal staining	No loss	No loss	loss
M1/19-1.3	transverse	adenocarcinoma	moderately	25	MSI-H	loss	No loss	No loss	loss
M1/19-2	caecum	adenocarcinoma	moderately	0	MSI-H	weak focal staining	No loss	No loss	loss
M1/19-3	small bowel	adenocarcinoma	moderately	0	MSI-H	loss	No loss	ND ^b	ND
M1/19-4	caecum	adenocarcinoma	poorly	0	MSI-H	loss	No loss	ND	loss
M1/19-4.2	descending	adenocarcinoma	moderately	10	MSI-H	loss	No loss	No loss	loss
M1/19-4.3	transverse	adenocarcinoma	moderately	30	MSI-H	weak focal staining	No loss	No loss	loss
M1/19-4.4	Vater ampulla	adenocarcinoma	well	>50	MSI-H	weak focal staining	No loss	No loss	loss
M1/19-5	caecum	adenocarcinoma	moderately	20	MSI-H	weak focal staining	No loss	No loss	loss
M1/19-5	ascending	adenocarcinoma	moderately	0	MSI-H	No loss	No loss	No loss	loss
M1/19-5	endometrium	adenocarcinoma	well	0	MSI-L	No loss	No loss	No loss	loss
M1/19-5.2	splenic flexure	adenocarcinoma	poorly	10	MSI-H	weak focal staining	No loss	No loss	loss
M1/19-5.3	ascending	adenocarcinoma	well	5	MSI-H	loss	No loss	No loss	loss
M1/19-5.3	endometrium	endometrioid adenocarcinoma	well	0	MSI-H	weak focal staining	No loss	No loss	loss
M1/19-5.4	hepatic flexure	adenocarcinoma	poorly	0	MSI-H	loss	No loss	No loss	loss
M1/19-6	splenic flexure	adenocarcinoma	poorly	>50	MSI-H	loss	No loss	ND	ND
M1/19-7	caecum	adenocarcinoma	moderately	signet ring cells	MSI-H	loss	No loss	No loss	loss
M1/19-8	caecum	adenocarcinoma	poorly	>50	MSI-H	No loss	No loss	No loss	loss
M1/19-9	ascending	adenocarcinoma	poorly	<5	MSI-H	loss	No loss	No loss	loss
M1/19-10	rectum	adenocarcinoma	poorly	45	MSI-H	loss	No loss	No loss	loss
M1/19-10.2	ascending	adenocarcinoma	moderately	10	MSI-H	weak focal staining	No loss	No loss	loss
M1/19-11	transverse	adenocarcinoma, signet ring cells	poorly	>50, signet ring cells	MSI-H	focal staining	No loss	No loss	loss
M1/19-11.2	sigmoid	adenocarcinoma	moderately	0	MSI-H	loss	No loss	No loss	loss

^a Probands were coded as M1/19 followed by a number from 1 to 11. The .2, .3, etc. subcodes indicate different affected individuals belonging to the same family. ^bND = not determined

Table 4 Haplotypes identified in 11 probands with the MLH1 c.2252_2253delAA mutation

Markers on chromosome 3:	M1/19-1		M1/19-2		M1/19-3		M1/19-4		M1/19-5		M1/19-6	
D3S1277	285	297	283	281	283	291	283	291	283	285	285	291
D3S1561	246	246	246	262	246	246	258	248	260	248	246	262
<i>16xTG</i>	243	243	243	247	243	249	243	249	243	243	243	249
<i>19xAC</i>	230	226	230	224	230	224	230	224	230	224	230	222
<i>14xAC</i>	178	180	178	184	178	180	178	180	(178)	(184)	178	180
<i>rs1800734</i>	G	G	G	A	G	G	G	G	G	G	G	G
<i>rs3774341</i>	A	A	A	A	A	C	A	C	A	A	A	C
<i>rs1799977</i>	A	A	A	A	A	G	A	G	A	A	A	G
<i>rs1558528</i>	C	C	C	C	C	A	C	A	C	C	C	A
<i>rs9876116</i>	A	A	A	A	A	G	A	G	A	A	A	G
c.2252_2253delAA	mut^a	wt ^b	mut	wt	mut	wt	mut	wt	mut	wt	mut	wt
<i>rs193922366*</i>	–	CTT	–	CTT	–	CTT	–	CTT	–	CTT	–	CTT
<i>rs749072</i>	T	T	T	C	T	T	T	T	(T)	(C)	T	T
<i>D3S1298</i>	225	229	225	231	225	213	225	219	225	219	225	227
<i>D3S1260</i>	286	284	286	290	286	284	286	286	286	274	286	286
<i>18xAC</i>	212	222	212	210	212	214	212	206	212	218	212	210
19xGA	172	172	172/178		170	168	172	172	172	172	172	168
D3S3685	236	238	220	228	220	234	236	226	238	236	238	228

M1/19-7	M1/19-8	M1/19-9	M1/19-10	M1/19-11
283/291	283/285	283/285	283 291	283 285
246/266	260/264	260/266	262 246	246 246
(243) (249)	(243) (249)	243 243	243 249	243 249
(230) (224)	(230) (224)	(230) (226)	230 224	230 222
(178) (180)	(178) (180)	(178) (180)	178 180	178 180
(G) (A)	G G	G G	G G	G G
A A	A C	A A	A C	A C
A A	A G	A A	A G	A A
C C	C A	C C	C A	C A
A A	A G	A A	A G	A G
mut wt	mut wt	mut wt	mut wt	mut wt
(–) (CTT)	(–) (CTT)	(–) (CTT)	– CTT	– CTT
(T) (C)	T T	T T	T T	T T
225 225	225 225	225 225	225 231	225 217
286 286	286 286	286 286	286 286	286 286
212 212	212 214	(212) (222)	212 206	212 222
172 172	172 172	172/174	172 172	168 168
222/230	236 238	230/236	230 236	232 238

*rs193922366 is a three-nucleotide ins/del: CTT/-; ^amut = mutated allele, ^bwt = wild-type allele.

The haplotype carrying the mutation is shown in bold. The 1.7 Mb region defined by the haplotype shared by all mutation carriers is marked in italics.

For non informative markers inside the shared region, alleles have been attributed based on the haplotype carrying the mutation identified in informative families and are shown in brackets.

For non informative markers outside the shared region, alleles could not be attributed and are separated by a "/".